These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 8867855)

  • 41. Trypanosoma cruzi-sensitized T-lymphocyte mediated 51CR release from human heart cells in Chagas' disease.
    Teixeira AR; Teixeira G; Macêdo V; Prata A
    Am J Trop Med Hyg; 1978 Nov; 27(6):1097-1107. PubMed ID: 83110
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lymphoblast transformation as a measure of immune competence during experimental Chagas' disease.
    Cunningham DS; Kuhn RE
    J Parasitol; 1980 Jun; 66(3):390-8. PubMed ID: 6771376
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Immunology of Chagas' disease].
    Abath FG
    Rev Bras Malariol Doencas Trop; 1983; 35():101-8. PubMed ID: 6438706
    [No Abstract]   [Full Text] [Related]  

  • 44. Modification of T-cell proliferation and interleukin 2 production in mice infected with Trypanosoma cruzi.
    Harel-Bellan A; Joskowicz M; Fradelizi D; Eisen H
    Proc Natl Acad Sci U S A; 1983 Jun; 80(11):3466-9. PubMed ID: 6407015
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Increased resistance to Aeromonas hydrophila in mice experimentally infected with Trypanosoma cruzi.
    Cunningham DS; Hazen TC; Kuhn RE
    J Parasitol; 1981 Aug; 67(4):468-74. PubMed ID: 6790693
    [No Abstract]   [Full Text] [Related]  

  • 46. Polyclonal cell activity of a repeat peptide derived from the sequence of an 85-kilodalton surface protein of Trypanosoma cruzi trypomastigotes.
    Pestel J; Defoort JP; Gras-Masse H; Afchain D; Capron A; Tartar A; Ouaissi A
    Infect Immun; 1992 Feb; 60(2):715-9. PubMed ID: 1730508
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Plasma membrane origin on Trypanosoma cruzi antigenic determinants in Chagas' disease.
    Carniol C; Neves M; Zingales B; de Araujo PS; Colli W
    Rev Inst Med Trop Sao Paulo; 1982; 24(2):83-7. PubMed ID: 6182595
    [No Abstract]   [Full Text] [Related]  

  • 48. Experimental Chagas' disease: protective activity in relation with subcellular fractions of the parasite.
    Segura EL; Paulone I; Cerisola J; Cappa SM
    J Parasitol; 1976 Feb; 62(1):131-3. PubMed ID: 815533
    [No Abstract]   [Full Text] [Related]  

  • 49. Trypanosoma cruzi: responses by cells from infected mice to alloantigens.
    Cunningham DS; Kuhn RE; Hatcher FM
    Exp Parasitol; 1981 Feb; 51(1):141-51. PubMed ID: 6450686
    [No Abstract]   [Full Text] [Related]  

  • 50. [Deposition of immune complexes in experimental Chagas' disease].
    Chaves J; Mariano ON; de Souza HB; Irulegui I; Vaz CA
    Rev Inst Med Trop Sao Paulo; 1982; 24(1):11-5. PubMed ID: 6214838
    [No Abstract]   [Full Text] [Related]  

  • 51. Antigen-specific T-helper cells abrogate suppression in Trypanosoma cruzi-infected mice.
    Ritter DM; Kuhn RE
    Infect Immun; 1990 Oct; 58(10):3248-56. PubMed ID: 1698177
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunosuppression in mice infected with Trypanosoma cruzi (Chagas, 1909). II--Trypomastigote crude extract (TCE) suppress the humoral immune response in mice.
    Corsini AC; Costa MG
    Rev Inst Med Trop Sao Paulo; 1981; 23(3):122-6. PubMed ID: 6792689
    [No Abstract]   [Full Text] [Related]  

  • 53. Trypanosoma cruzi cleaves galectin-3 N-terminal domain to suppress its innate microbicidal activity.
    Pineda M; Corvo L; Callejas-Hernández F; Fresno M; Bonay P
    Clin Exp Immunol; 2020 Feb; 199(2):216-229. PubMed ID: 31593356
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Possible use of tissue amastigotes of T. cruzi for serological immunofluorescence tests].
    Cossio PM; Casanova MB; González Cappa S; Fernández L; Arana RM
    Medicina (B Aires); 1983; 43(6 Pt 1):737-8. PubMed ID: 6433144
    [No Abstract]   [Full Text] [Related]  

  • 55. The effect of heterologous anti-thymocyte serum upon the course of infection with Trypanosoma cruzi in Mice.
    Vilches AM; Katzin A; Golfera H; Schmunis GA
    Z Tropenmed Parasitol; 1973 Sep; 24(3):279-84. PubMed ID: 4200671
    [No Abstract]   [Full Text] [Related]  

  • 56. Trypanosoma cruzi: in vivo and in vitro correlation between T-cell activation and susceptibility in inbred strains of mice.
    Nogueira N; Ellis J; Chaplan S; Cohn Z
    Exp Parasitol; 1981 Jun; 51(3):325-34. PubMed ID: 6785102
    [No Abstract]   [Full Text] [Related]  

  • 57. [Histocompatibility antigens and Chagas' disease].
    Figueiredo MJ; Bittencourt LA; de Almeida EA
    Arq Bras Cardiol; 1989 Dec; 53(6):347-8. PubMed ID: 2517715
    [No Abstract]   [Full Text] [Related]  

  • 58. Chagas' disease: potential for immunoprophylaxis.
    Lancet; 1980 Mar; 1(8166):466. PubMed ID: 6102192
    [No Abstract]   [Full Text] [Related]  

  • 59. Trypanosoma cruzi immunosuppressive factor decreases the interleukin-2 mRNA level in cultured normal activated human lymphocytes.
    Majumder S; Kierszenbaum F
    Infect Immun; 1995 Nov; 63(11):4546-9. PubMed ID: 7591102
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Trypanosoma cruzi: ability of T-cell-enriched and -depleted lymphocyte populations to passively protect mice.
    Trischmann TM; Bloom BR
    Exp Parasitol; 1980 Apr; 49(2):225-32. PubMed ID: 6767621
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.